JP2002528123A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002528123A5 JP2002528123A5 JP2000579757A JP2000579757A JP2002528123A5 JP 2002528123 A5 JP2002528123 A5 JP 2002528123A5 JP 2000579757 A JP2000579757 A JP 2000579757A JP 2000579757 A JP2000579757 A JP 2000579757A JP 2002528123 A5 JP2002528123 A5 JP 2002528123A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid sequence
- antigen
- sequence
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000007523 nucleic acids Chemical class 0.000 description 53
- 108091028043 Nucleic acid sequence Proteins 0.000 description 40
- 239000003814 drug Substances 0.000 description 27
- 239000000427 antigen Substances 0.000 description 24
- 102000036639 antigens Human genes 0.000 description 23
- 108091007433 antigens Proteins 0.000 description 23
- 229940079593 drug Drugs 0.000 description 15
- 108020004707 nucleic acids Proteins 0.000 description 15
- 102000039446 nucleic acids Human genes 0.000 description 15
- 239000013604 expression vector Substances 0.000 description 14
- 239000002245 particle Substances 0.000 description 11
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 230000001461 cytolytic effect Effects 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 101710132601 Capsid protein Proteins 0.000 description 5
- 241000700721 Hepatitis B virus Species 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 244000053095 fungal pathogen Species 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 244000052613 viral pathogen Species 0.000 description 3
- 241000700605 Viruses Species 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10716998P | 1998-11-05 | 1998-11-05 | |
| US60/107,169 | 1998-11-05 | ||
| PCT/US1999/026291 WO2000026385A1 (en) | 1998-11-05 | 1999-11-05 | Nucleic acid constructs for genetic immunization |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002528123A JP2002528123A (ja) | 2002-09-03 |
| JP2002528123A5 true JP2002528123A5 (cg-RX-API-DMAC7.html) | 2006-12-21 |
Family
ID=22315199
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000579757A Pending JP2002528123A (ja) | 1998-11-05 | 1999-11-05 | 遺伝子免疫のための核酸構築物 |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1119630B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2002528123A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE315658T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU775939B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2349505A1 (cg-RX-API-DMAC7.html) |
| CY (1) | CY1105600T1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE69929470T2 (cg-RX-API-DMAC7.html) |
| DK (1) | DK1119630T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2257879T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL142980A0 (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ512078A (cg-RX-API-DMAC7.html) |
| PT (1) | PT1119630E (cg-RX-API-DMAC7.html) |
| WO (1) | WO2000026385A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002024887A2 (en) * | 2000-09-19 | 2002-03-28 | Tripep Ab | Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen |
| US6933366B2 (en) | 1996-12-27 | 2005-08-23 | Tripep Ab | Specificity exchangers that redirect antibodies to bacterial adhesion receptors |
| US6660842B1 (en) | 1994-04-28 | 2003-12-09 | Tripep Ab | Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen |
| EP1220697B1 (en) | 1999-10-11 | 2004-12-29 | Felton International, Inc. | Universal anti-infectious protector for needleless injectors |
| US7887506B1 (en) | 1999-11-23 | 2011-02-15 | Pulse Needlefree Systems, Inc. | Safety mechanism to prevent accidental patient injection and methods of same |
| ATE320493T1 (de) * | 2000-06-22 | 2006-04-15 | Ucb Pharma Ltd | Modifizierung des hepatitis b kernantigens |
| BR0209854A (pt) * | 2001-05-18 | 2004-06-08 | Powderject Vaccines Inc | Molécula de ácido nucléico recombinante, cassete de expressão, vetor, polipeptìdeo, composição de vacina, dispositivo de aceleração de partìcula, e, método para gerar uma resposta imune celular em um indivìduo |
| DE10143490C2 (de) * | 2001-09-05 | 2003-12-11 | Gsf Forschungszentrum Umwelt | Rekombinantes MVA mit der Fähigkeit zur Expression von HCV Struktur-Antigenen |
| NZ539107A (en) | 2002-09-27 | 2008-11-28 | Powderject Res Ltd | Nucleic acid coated particles |
| US7335359B2 (en) | 2003-02-06 | 2008-02-26 | Tripep Ab | Glycosylated specificity exchangers |
| CN1747970A (zh) | 2003-02-06 | 2006-03-15 | 三肽公司 | 抗原/抗体或配体/受体糖基化的特异性交换剂 |
| CA2702340C (en) | 2006-10-12 | 2014-12-16 | The University Of Queensland | Compositions and methods for modulating immune responses |
| BRPI0922561A2 (pt) | 2008-12-09 | 2020-08-11 | Pfizer Vaccines Llc | vacina de peptídeo de ch3 da ige. |
| CN102596236B (zh) | 2009-07-30 | 2015-06-24 | 辉瑞疫苗有限责任公司 | 抗原性Tau肽及其用途 |
| KR101660578B1 (ko) | 2009-09-03 | 2016-09-27 | 화이자 백신스 엘엘씨 | Pcsk9 백신 |
| EP2575868A1 (en) | 2010-06-07 | 2013-04-10 | Pfizer Vaccines LLC | Ige ch3 peptide vaccine |
| BR112013010926A2 (pt) | 2010-11-01 | 2016-08-23 | Univ Technology Sidney | agentes imunomoduladores e seus usos |
| US9403879B2 (en) * | 2011-02-11 | 2016-08-02 | The Trustees Of The University Of Pennsylvania | Nucleic acid molecule encoding hepatitis B virus core protein and vaccine comprising the same |
| WO2012131504A1 (en) | 2011-03-02 | 2012-10-04 | Pfizer Inc. | Pcsk9 vaccine |
-
1999
- 1999-11-05 DK DK99963869T patent/DK1119630T3/da active
- 1999-11-05 AT AT99963869T patent/ATE315658T1/de not_active IP Right Cessation
- 1999-11-05 ES ES99963869T patent/ES2257879T3/es not_active Expired - Lifetime
- 1999-11-05 NZ NZ512078A patent/NZ512078A/xx not_active IP Right Cessation
- 1999-11-05 AU AU20222/00A patent/AU775939B2/en not_active Ceased
- 1999-11-05 IL IL14298099A patent/IL142980A0/xx unknown
- 1999-11-05 WO PCT/US1999/026291 patent/WO2000026385A1/en not_active Ceased
- 1999-11-05 JP JP2000579757A patent/JP2002528123A/ja active Pending
- 1999-11-05 PT PT99963869T patent/PT1119630E/pt unknown
- 1999-11-05 EP EP99963869A patent/EP1119630B1/en not_active Expired - Lifetime
- 1999-11-05 DE DE69929470T patent/DE69929470T2/de not_active Expired - Lifetime
- 1999-11-05 CA CA002349505A patent/CA2349505A1/en not_active Abandoned
-
2006
- 2006-04-07 CY CY20061100494T patent/CY1105600T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ulrich et al. | Core particles of hepatitis B virus as carrier for foreign epitopes | |
| Celis et al. | Antibodies to hepatitis B surface antigen potentiate the response of human T lymphocyte clones to the same antigen | |
| EP1685251B1 (en) | Nucleic acid constructs | |
| JP2004527213A5 (cg-RX-API-DMAC7.html) | ||
| JP2002512026A5 (cg-RX-API-DMAC7.html) | ||
| JP2002528060A5 (cg-RX-API-DMAC7.html) | ||
| CA2325566A1 (en) | Vaccine formulations comprising antiidiotypic antibodies which immunologically mimic group b streptococcal carbohydrates | |
| CA2413546A1 (en) | Modification of hepatitis b core antigen | |
| JP2001512748A5 (cg-RX-API-DMAC7.html) | ||
| CA2305683A1 (en) | Immunogenic peptides from the hpv e7 protein | |
| US6492145B1 (en) | Vaccine against mycobacterial infections | |
| JP2002517249A5 (cg-RX-API-DMAC7.html) | ||
| EP1075520A1 (en) | Introduction of naked dna or rna encoding non-human vertebrate peptide hormones or cytokines into a non-human vertebrate | |
| Morgan et al. | Comparative immunogenicity studies on Epstein‐Barr virus membrane antigen (MA) gp340 with novel adjuvants in mice, rabbits, and cotton‐top tamarins | |
| US6221664B1 (en) | Composite vaccine which contains antigen, antibody and recombinant DNA and its preparing method | |
| JP2010538629A (ja) | 外来エピトープを含む組換え偽ウイルスの発現および分泌を可能とするポリヌクレオチド、それらの製造および使用 | |
| JP2004536107A5 (cg-RX-API-DMAC7.html) | ||
| Chengalvala et al. | Enhanced immunogenicity of hepatitis B surface antigen by insertion of a helper T cell epitope from tetanus toxoid | |
| JP2002516662A5 (cg-RX-API-DMAC7.html) | ||
| CN118286410B (zh) | 一种偶联CD8抗体的肿瘤mRNA疫苗的制备方法 | |
| Sjolander et al. | Bacterial Expression Systems Based on a Protein A and Protein G Designed for the Production of Immunogens: Applications to Plasmodium falciparum Malaria Antigens | |
| AU700104B2 (en) | Prolactin as a vaccine adjuvant | |
| JP2003286189A (ja) | 中空ナノ粒子を形成するタンパク質に疾患治療用の細胞導入物質を融合させた薬剤 | |
| KR100905249B1 (ko) | Dna와 항원의 조합에 의해 효능이 증강된 백신포뮬레이션 | |
| Sanchez et al. | Evidence for the presence of repeating antigenic determinants in the major and minor polypeptides derived from hepatitis B surface antigen |